GlaxoSmithKline has announced that 191 out of 347 workers at its Ulverston site will be losing their jobs beginning in June 2019. The next wave of staff will leave by 2020.
According to the company, its sterile injecables part department will close because it was not cost effective. The facility itself will not close as the tablet manufacturing department will see further development.
GSK had originally planned a major biologics plant at the site, but announced in July 2017 that it would not move forward with the planned expansion.
Read the report from the Westmorland Gazette